Active Pharmaceutical Ingredients
Dipyridamole ER (Extended Release) Coated Pellets are specialized multiarticulate dosage forms designed for sustained release of Dipyridamole, a platelet aggregation inhibitor and vasodilator. These pellets are intended for use in the formulation of capsules or tablets, providing controlled and prolonged therapeutic action.
| Component | Function |
|---|---|
| Dipyridamole | Active Pharmaceutical Ingredient (API) |
| Sugar Spheres / MCC Spheres | Inert core or starter pellets |
| Hydroxypropyl Methylcellulose (HPMC) | Binder / Film former during layering |
| Talc / Colloidal Silicon Dioxide | Anti-adherent / Glidant |
| Eudragit RS / Eudragit RL | Extended-release polymer (controls drug release rate) |
| Triethyl Citrate / PEG 6000 | Plasticizer (for coating) |
| Purified Water | Solvent (removed after processing) |
Outsourcing pellets through a trusted partner like Salius Pharma can be a strategic decision to save both time and resources, without compromising on quality or compliance. Instead, partnering with Salius Pharma—a leading distributor aligned with USFDA-approved and WHO-GMP-certified manufacturers in India—allows you to leverage high-quality products, seamless logistics, and professional support under one roof.
We ensure prompt and reliable shipping worldwide. Delivery times may vary depending on destination, order volume, and regulatory requirements.
Looking to source Dipyridamole ER Coated or other high-quality pharmaceutical pellet formulations?
Whether you need Active Pharmaceutical Ingredients (APIs), excipients, or regulatory support, our team is ready to provide reliable, compliant, and cost-effective solutions tailored to your market needs.
The contents of this page and any attachments are intended solely for the designated recipient(s) and may contain confidential and/or privileged information protected by law.
Any patented products are excluded from our offerings in regions where such patents are currently in force.
Dipyridamole ER Coated Pellets are used in the formulation of extended-release capsules or tablets, mainly for the prevention of thromboembolic complications and as an adjunct in cardiovascular therapies.
Yes. They are often used in fixed-dose combinations (e.g., with Aspirin) to enhance antiplatelet efficacy and provide synergistic therapeutic benefits.
Dipyridamole ER Coated Pellets are typically tested as per USP, BP, and EP pharmacopoeia standards, with validated HPLC methods for identification and assay.
Yes. Technical documentation, dissolution profiles, and formulation guidance can be provided to support product registration and development.